Get the Stockscreener App
3.99
0.50%
0.02
After Hours:
3.98
-0.01
-0.25%
Incannex Healthcare Inc stock is traded at $3.99, with a volume of 313.79K.
It is up +0.50% in the last 24 hours and up +36.64% over the past month.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
See More
Previous Close:
$3.97
Open:
$3.94
24h Volume:
313.79K
Relative Volume:
0.86
Market Cap:
$47.74M
Revenue:
$12,000
Net Income/Loss:
$-48.50M
P/E Ratio:
-0.2338
EPS:
-17.0687
Net Cash Flow:
$-19.78M
1W Performance:
+10.22%
1M Performance:
+36.64%
6M Performance:
-67.21%
1Y Performance:
-36.49%
1-Day Range:
$3.75
$4.01
1-Week Range:
$3.56
$4.025
52-Week Range:
$2.49
$49.80
Incannex Healthcare Inc Stock (IXHL) Company Profile
Name
Incannex Healthcare Inc
Sector
Phone
61 409 840 786
Address
8 CENTURY CIRCUIT, NORWEST NSW
Compare IXHL vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
3.99 | 44.99M | 12,000 | -48.50M | -19.78M | -17.07 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Incannex Healthcare Inc Stock (IXHL) Latest News
Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025. - marketscreener.com
Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
IXHL Forecast — Price Target — Prediction for 2027 - TradingView
Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality - Manufacturing Chemist
Incannex Healthcare Inc. Actuals & Estimates (NASDAQ:IXHL) - TradingView
Incannex Healthcare Inc (IXHL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why Did IXHL Stock Tank Over 32% Today? - Stocktwits
A2DF4D Forecast — Price Target — Prediction for 2027 - TradingView
Incannex receives U.S. patent for sleep apnea drug IHL-42X - Investing.com
Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea - marketscreener.com
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea - The Manila Times
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Incannex's sleep apnea drug gets U.S. patent protection to 2040 - Stock Titan
Incannex (IXHL) secures long-dated U.S. patent for IHL-42X sleep apnoea therapy - Stock Titan
Incannex Healthcare Inc (IXHL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incannex Healthcare Inc (IXHL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Is Incannex (ASX:IHL) Emerging as a Clinical Cannabis Story? - Kalkine Media
IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits
Incannex Healthcare Inc (IXHL) Institutional Confidence - TradingKey
Incannex Healthcare Inc (IXHL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Incannex Healthcare (IXHL) Proxy Filing Summary - Quartr
Incannex Healthcare receives A$6m R&D tax incentive payment By Investing.com - Investing.com Nigeria
IXHL Stock Gains As Incannex Reactivates Share Repurchase Program - Stocktwits
IXHL Should I Buy - Intellectia AI
Incannex Healthcare Inc (IXHL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incannex Healthcare Inc (IXHL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Incannex Healthcare Inc (IXHL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
$Incannex Healthcare (IXHL.US)$ - Moomoo
Incannex Healthcare receives A$6m R&D tax incentive payment - Investing.com UK
Incannex Healthcare Secures Major Non-Dilutive R&D Funding - TipRanks
Incannex Healthcare Secures Over A$11 Million in Non-Dilutive Capital Through Australian R&D Tax Incentive Program - Quiver Quantitative
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility - The Manila Times
Incannex lines up A$11m in non‑dilutive cash to advance IHL‑42X study - Stock Titan
Incannex Receives A$6.0M R&D Tax Refund, Expects A$11.1M+ in Non-Dilutive Funding - TradingView
Incannex (Nasdaq: IXHL) secures over A$11.1M in R&D tax incentives - Stock Titan
Incannex Healthcare: Target Price Consensus and Analysts Recommendations | IQI | AU000000IHL8 - marketscreener.com
Incannex Healthcare Gains Independent Buy-Rated Research Coverage - TipRanks
Sleep apnea and anxiety drug developer Incannex gets AGP buy rating at $18 - Stock Titan
Incannex Healthcare: Alliance Global Partners Starts Coverage with $18 Price Target - TradingView
Alliance Global initiates Incannex (IXHL) equity research coverage on key drug pipeline - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
$Incannex Healthcare (IXHL.US)$ [Onlooker][OK] - Moomoo
INCANNEX HEALTHCARE INC (IXHL) Stock Chart - ChartMill
Incannex Healthcare Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D InvestmentOperating Income Trends - newsline.com
Why Are ASX Cannabis Stocks Drawing Fresh Attention? - Kalkine Media
Incannex Healthcare Inc Stock (IXHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):